Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors

References

• Teicher BA, Liu SD, Liu JT, et al. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res. 1993;13:1549–1556.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7:168–181.
   PubMed Web of Science ®Google Scholar
• Puscas I, Coltau M, Farcau D, et al. Carbonic anhydrase and cancer. In: Puscas I, editor. Carbonic anhydrase and modulation of physiologic and pathologic processes in the organism. Timisoara, Romania: Helicon Press; 1994. p. 551–558.
   Google Scholar
• Buzás GM, Supuran CT. The history and rationale of using carbonic anhydrase inhibitors in the treatment of peptic ulcers. In memoriam Ioan Puşcaş (1932–2015). J Enzyme Inhib Med Chem. 2016;31:527–533.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors: aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors. J Enzyme Inhib. 2000;15:597–610.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors–part 94. 1,3,4-thiadiazole-2-sulfonamide derivatives as antitumor agents? Eur J Med Chem. 2000;35:867–874.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Briganti F, Tilli S, et al. Carbonic anhydrase inhibitors: sulfonamides as antitumor agents? Bioorg Med Chem. 2001;9:703–714.
   PubMed Web of Science ®Google Scholar
• Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev. 2012;112:4421–4468.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Structure and function of carbonic anhydrases. Biochem J. 2016;473:2023–2032.
   PubMed Web of Science ®Google Scholar
• Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem. 2016;31:345–360.
   PubMed Web of Science ®Google Scholar
• Pastorek J, Pastoreková S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene. 1994;9:2877–2888.
   PubMed Web of Science ®Google Scholar
• Türeci O, Sahin U, Vollmar E, et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci U S A. 1998;95:7608–7613.
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10:767–777.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov. 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005–2013). Expert Opin Ther Pat. 2013;23:681–691.
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: a patent review 2007–2011. Expert Opin Ther Pat. 2012;22:79–88.
   PubMed Web of Science ®Google Scholar
• Masini E, Carta F, Scozzafava A, et al. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23:705–716.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat. 2013;23:725–735.
   PubMed Web of Science ®Google Scholar
• Thiry A, Dognè JM, Masereel B, et al. Carbonic anhydrase inhibitors as anticonvulsant agents. Curr Top Med Chem. 2007;7:855–864.
   PubMed Web of Science ®Google Scholar
• Aggarwal M, Kondeti B, McKenna R. Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23:717–724.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Rev Neurother. 2015;15:851–856.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol. 2016;12:423–431.
   PubMed Web of Science ®Google Scholar
• Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. J Enzyme Inhib Med Chem. 2016;31:894–899.
   PubMed Web of Science ®Google Scholar
• Carta F. Di Cesare Mannelli L, Pinard M, et al. A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects. Bioorg Med Chem. 2015;23:1828–1840.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother. 2016;16:961–968.
   PubMed Web of Science ®Google Scholar
• Margheri F, Ceruso M, Carta F, et al. Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium. J Enzyme Inhib Med Chem. 2016;31(Suppl 4):60–63.
   PubMed Web of Science ®Google Scholar
• Bua S, Di Cesare Mannelli L, Vullo D, et al. Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis. J Med Chem. 2017;60:1159–1170.
   PubMed Web of Science ®Google Scholar
• Carta F, Scozzafava A, Supuran CT. Sulfonamides (RSO2NH2): a patent review 2008–2012. Expert Opin Ther Pat. 2012;22:747–758.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Carta F, Supuran CT. Secondary and tertiary sulfonamides: a patent review (2008–2012). Expert Opin Ther Pat. 2013;23:203–213.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Indisulam: an anticancer sulfonamide in clinical development. Expert Opin Investig Drugs. 2003;12:283–287.
   PubMed Web of Science ®Google Scholar
• Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008–2013). Expert Opin Ther Pat. 2013;23:737–749.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60:7075–7083.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Beasley N, Watson PH, et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol. 2001;158:1011–1019.
   PubMed Web of Science ®Google Scholar
• Beasley NJ, Wykoff CC, Watson PH, et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 2001;61:5262–5267.
   PubMed Web of Science ®Google Scholar
• Loncaster JA, Harris AL, Davidson SE, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001;61:6394–6399.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 2001;61:7992–7998.
   PubMed Web of Science ®Google Scholar
• Turner KJ, Crew JP, Wykoff CC, et al. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer. 2002;86:1276–1282.
   PubMed Web of Science ®Google Scholar
• Mandriota SJ, Turner KJ, Davies DR, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell. 2002;1:459–468.
   PubMed Web of Science ®Google Scholar
• Stessels F, Van Den Eynden G, Van der Auwera I, et al. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer. 2004;90:1429–1436.
   PubMed Web of Science ®Google Scholar
• Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol. 2001;19:3660–3668.
   PubMed Web of Science ®Google Scholar
• Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437–443.
   PubMed Web of Science ®Google Scholar
• Svastová E, Hulíková A, Rafajová M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004;577:439–445.
   PubMed Web of Science ®Google Scholar
• Cecchi A, Hulikova A, Pastorek J, et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem. 2005;48:4834–4841.
   PubMed Web of Science ®Google Scholar
• Schwartz L, Supuran CT, Alfarouk KO. The Warburg effect and the hallmarks of cancer. Anticancer Agents Med Chem. 2017;17:164–170.
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123:309–314.
   PubMed Web of Science ®Google Scholar
• Swietach P, Wigfield S, Cobden P, et al. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem. 2008;283:20473–20483.
   PubMed Web of Science ®Google Scholar
• Swietach P, Patiar S, Supuran CT, et al. The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. J Biol Chem. 2009;284:20299–20310.
   PubMed Web of Science ®Google Scholar
• Dubois L, Douma K, Supuran CT, et al. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol. 2007;83:367–373.
   PubMed Web of Science ®Google Scholar
• Dubois L, Lieuwes NG, Maresca A, et al. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol. 2009;92:423–428.
   PubMed Web of Science ®Google Scholar
• Dubois L, Peeters S, Lieuwes NG, et al. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol. 2011;99:424–431.
   PubMed Web of Science ®Google Scholar
• Ebbesen P, Pettersen EO, Gorr TA, et al. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J Enzyme Inhib Med Chem. 2009;24(Suppl 1):1–39.
   PubMed Web of Science ®Google Scholar
• Pettersen EO, Ebbesen P, Gieling RG, et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem. 2015;30:689–721.
   PubMed Web of Science ®Google Scholar
• Ahlskog JK, Dumelin CE, Trüssel S, et al. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett. 2009;19:4851–4856.
   PubMed Web of Science ®Google Scholar
• Ahlskog JK, Schliemann C, Mårlind J, et al. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer. 2009;101:645–657.
   PubMed Web of Science ®Google Scholar
• Buller F, Steiner M, Frey K, et al. Selection of carbonic anhydrase IX inhibitors from one million DNA-encoded compounds. ACS Chem Biol. 2011;6:336–344.
   PubMed Web of Science ®Google Scholar
• Alterio V, Hilvo M, Di Fiore A, et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci USA. 2009;106:16233–16238.
   PubMed Web of Science ®Google Scholar
• Buanne P, Renzone G, Monteleone F, et al. Characterization of carbonic anhydrase IX interactome reveals proteins assisting its nuclear localization in hypoxic cells. J Proteome Res. 2013;12:282–292.
   PubMed Web of Science ®Google Scholar
• Buonanno M, Langella E, Zambrano N, et al. Disclosing the interaction of carbonic anhydrase IX with cullin-associated NEDD8-dissociated protein 1 by molecular modeling and integrated binding measurements. ACS Chem Biol. 2017;12:1460–1465.
   PubMed Web of Science ®Google Scholar
• Langella E, Buonanno M, Vullo D, et al. Biochemical, biophysical and molecular dynamics studies on the proteoglycan-like domain of carbonic anhydrase IX. Cell Mol Life Sci. 2018;75:3283–3296.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Alterio V, Di Fiore A, et al. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. Med Res Rev. 2018;38:1799–1836.
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011;71:3364–3376.
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem. 2011;54:1896–1902.
   PubMed Web of Science ®Google Scholar
• Touisni N, Maresca A, McDonald PC, et al. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J Med Chem. 2011;54:8271–8277.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Winum JY, Supuran CT, et al. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget. 2012;3:84–97.
   PubMed Web of Science ®Google Scholar
• Lock FE, McDonald PC, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. 2013;32:5210–5219.
   PubMed Web of Science ®Google Scholar
• Swayampakula M, McDonald PC, Vallejo M, et al. The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion. Oncogene. 2017;36:6244–6261.
   PubMed Web of Science ®Google Scholar
• Bozdag M, Carta F, Ceruso M, et al. Discovery of 4-hydroxy-3-(3-(phenylureido) benzenesulfonamides as SLC-0111 analogues for the treatment of hypoxic tumors overexpressing carbonic anhydrase IX. J Med Chem. 2018;61:6328–6338.
   PubMed Web of Science ®Google Scholar
• Owa T, Yoshino H, Okauchi T, et al. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem. 1999;42:3789–3799.
   PubMed Web of Science ®Google Scholar
• Abbate F, Casini A, Owa T, et al. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett. 2004;14:217–223.
   PubMed Web of Science ®Google Scholar
• [cited 2018 Sept 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT00165867
   Google Scholar
• Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun (Camb). 2010;46:8371–8373.
   PubMed Web of Science ®Google Scholar
• Mboge MY, Mahon BP, Lamas N, et al. Structure activity study of carbonic anhydrase IX: selective inhibition with ureido-substituted benzenesulfonamides. Eur J Med Chem. 2017;132:184–191.
   PubMed Web of Science ®Google Scholar
• [updated 2016 May 17; cited 2018 Sept 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT02215850
   Google Scholar
• [updated 2018 Mar 1; cited 2018 Sept 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT03450018
   Google Scholar
• Akurathi V, Dubois L, Lieuwes NG, et al. Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia. Nucl Med Biol. 2010;37:557–564.
   PubMed Web of Science ®Google Scholar
• Can D, Spingler B, Schmutz P, et al. [(Cp-R)M(CO)3] (M=Re or 99mTc) Arylsulfonamide, arylsulfamide, and arylsulfamate conjugates for selective targeting of human carbonic anhydrase IX. Angew Chem Int Ed Engl. 2012;51:3354–3357.
   PubMed Web of Science ®Google Scholar
• Pan J, Lau J, Mesak F, et al. Synthesis and evaluation of 18F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography. J Enzyme Inhib Med Chem. 2014;29:249–255.
   PubMed Web of Science ®Google Scholar
• Peeters SG, Dubois L, Lieuwes NG, et al. [(18)F]VM4-037 MicroPET imaging and biodistribution of two in vivo CAIX-expressing tumor models. Mol Imaging Biol. 2015;17:615–619.
   PubMed Web of Science ®Google Scholar
• Sneddon D, Poulsen SA. Agents described in the molecular imaging and contrast agent database for imaging carbonic anhydrase IX expression. J Enzyme Inhib Med Chem. 2014;29:753–763.
   PubMed Web of Science ®Google Scholar
• Lau J, Liu Z, Lin KS, et al. Trimeric radiofluorinated sulfonamide derivatives to achieve in vivo selectivity for carbonic anhydrase IX-targeted PET imaging. J Nucl Med. 2015;56:1434–1440.
   PubMed Web of Science ®Google Scholar
• Dilworth JR, Pascu SI, Waghorn PA, et al. Synthesis of sulfonamide conjugates of Cu(II), Ga(III), In(III), Re(V) and Zn(II) complexes: carbonic anhydrase inhibition studies and cellular imaging investigations. Dalton Trans. 2015;44:4859–4873.
   PubMed Web of Science ®Google Scholar
• Sneddon D, Niemans R, Bauwens M, et al. Synthesis and in vivo biological evaluation of (68)Ga-labeled carbonic anhydrase IX targeting small molecules for positron emission tomography. J Med Chem. 2016;59:6431–6443.
   PubMed Web of Science ®Google Scholar
• Krall N, Pretto F, Mattarella M, et al. A 99mTc-labeled ligand of carbonic anhydrase IX selectively targets renal cell carcinoma in vivo. J Nucl Med. 2016;57:943–949.
   PubMed Web of Science ®Google Scholar
• Lau J, Zhang Z, Jenni S, et al. PET imaging of carbonic anhydrase IX expression of HT-29 tumor xenograft mice with (68)Ga-labeled benzenesulfonamides. Mol Pharm. 2016;13:1137–1146.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lau J, Zhang C, et al. Design, synthesis and evaluation of 18F-labeled cationic carbonic anhydrase IX inhibitors for PET imaging. J Enzyme Inhib Med Chem. 2017;32:722–730.
   PubMed Web of Science ®Google Scholar
• Nakai M, Pan J, Lin KS, et al. Evaluation of 99mTc-sulfonamide and sulfocoumarin derivatives for imaging carbonic anhydrase IX expression. J Inorg Biochem. 2018;185:63–70.
   PubMed Web of Science ®Google Scholar
• Shabana AM, Mondal UK, Alam MR, et al. pH-sensitive multiligand gold nanoplatform targeting carbonic anhydrase IX enhances the delivery of doxorubicin to hypoxic tumor spheroids and overcomes the hypoxia-induced chemoresistance. ACS Appl Mater Interfaces. 2018;10:17792–17808.
   PubMed Web of Science ®Google Scholar
• Groves K, Bao B, Zhang J, et al. Synthesis and evaluation of near-infrared fluorescent sulfonamide derivatives for imaging of hypoxia-induced carbonic anhydrase IX expression in tumors. Bioorg Med Chem Lett. 2012;22:653–657.
   PubMed Web of Science ®Google Scholar
• Mboge MY, Mahon BP, McKenna R, et al. Carbonic anhydrases: role in pH control and cancer. Metabolites. 2018;8:E19.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites. 2017;7:E48.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases and metabolism. Metabolites. 2018;8:E25.
   PubMed Web of Science ®Google Scholar
• Krall N, Pretto F, Decurtins W, et al. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl. 2014;53:4231–4235.
   PubMed Web of Science ®Google Scholar
• Cazzamalli S, Ziffels B, Widmayer F, et al. Enhanced therapeutic activity of non-internalizing small-molecule-drug conjugates targeting carbonic anhydrase IX in combination with targeted interleukin-2. Clin Cancer Res. 2018;24:3656–3667.
   PubMed Web of Science ®Google Scholar
• Cazzamalli S, Dal Corso A, Widmayer F, et al. Chemically defined antibody- and small molecule-drug conjugates for in vivo tumor targeting applications: a comparative analysis. J Am Chem Soc. 2018;140:1617–1621.
   PubMed Web of Science ®Google Scholar
• Li Y, De Luca R, Cazzamalli S, et al. Versatile protein recognition by the encoded display of multiple chemical elements on a constant macrocyclic scaffold. Nat Chem. 2018;10:441–448.
   PubMed Web of Science ®Google Scholar
• Iessi E, Logozzi M, Mizzoni D, et al. Rethinking the combination of proton exchanger inhibitors in cancer therapy. Metabolites. 2018;8:E2.
   Web of Science ®Google Scholar
• Ward C, Meehan J, Gray M, et al. Carbonic anhydrase IX (CAIX), cancer, and radiation responsiveness. Metabolites. 2018;8:E13.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Swayampakula M, Dedhar S. Coordinated regulation of metabolic transporters and migration/invasion by carbonic anhydrase IX. Metabolites. 2018;8:E20.
   PubMed Web of Science ®Google Scholar
• Federici C, Lugini L, Marino ML, et al. Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells. J Enzyme Inhib Med Chem. 2016;31(Suppl 1):119–125.
   PubMedGoogle Scholar
• Andreucci E, Peppicelli S, Carta F, et al. Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis. J Mol Med (Berl). 2017;95:1341–1353.
   PubMed Web of Science ®Google Scholar
• Kuchuk O, Tuccitto A, Citterio D, et al. pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma. Oncoimmunology. 2018;7:e1445452.
   PubMed Web of Science ®Google Scholar
• Bryant JL, Gieling RG, Meredith SL, et al. Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer. Int J Cancer. 2018;142:191–201.
   PubMed Web of Science ®Google Scholar
• Logsdon DP, Grimard M, Luo M, et al. Regulation of HIF1α under hypoxia by APE1/Ref-1 impacts CA9 expression: dual targeting in patient-derived 3D pancreatic cancer models. Mol Cancer Ther. 2016;15:2722–2732.
   PubMed Web of Science ®Google Scholar
• Boyd NH, Walker K, Fried J, et al. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight. 2017;2:92928.
   PubMed Web of Science ®Google Scholar
• Whitesides GM, Ismagilov RF. Complexity in chemistry. Science. 1999;284:89–92.
   PubMed Web of Science ®Google Scholar